Similarly, low dose HDAC inhibitors increased the release of GM-CSF from acute myeloid leukemia cells [65] and class I HDAC inhibition increased its expression in fibroblasts [66]. This evidence concerns the gene HDAC9 and acute myeloid leukemia.